MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

PHR.US

16.1

-2.6%↓

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

9.32 1.75

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.05

Max

9.4

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

129.143

87.826

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+25.23% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 25. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-439M

1.4B

Iepriekšējā atvēršanas cena

7.57

Iepriekšējā slēgšanas cena

9.32

Ziņu noskaņojums

By Acuity

50%

50%

183 / 361 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. janv. 19:05 UTC

Galvenie tirgus virzītāji

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

2026. g. 13. janv. 23:41 UTC

Tirgus saruna

Nikkei May Rise on Japan Election Hopes -- Market Talk

2026. g. 13. janv. 23:41 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 13. janv. 23:33 UTC

Tirgus saruna

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

2026. g. 13. janv. 23:13 UTC

Iegādes, apvienošanās, pārņemšana

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

2026. g. 13. janv. 23:10 UTC

Iegādes, apvienošanās, pārņemšana

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

2026. g. 13. janv. 23:03 UTC

Tirgus saruna

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

2026. g. 13. janv. 21:50 UTC

Iegādes, apvienošanās, pārņemšana

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

2026. g. 13. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 13. janv. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

2026. g. 13. janv. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

2026. g. 13. janv. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

2026. g. 13. janv. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

VERSANT Completes Acquisition Of Free TV Networks >VSNT

2026. g. 13. janv. 21:08 UTC

Iegādes, apvienošanās, pārņemšana

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

2026. g. 13. janv. 20:39 UTC

Tirgus saruna

Silver Settles at Another New High -- Market Talk

2026. g. 13. janv. 20:21 UTC

Tirgus saruna

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

2026. g. 13. janv. 20:17 UTC

Tirgus saruna

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

2026. g. 13. janv. 19:08 UTC

Iegādes, apvienošanās, pārņemšana

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

2026. g. 13. janv. 19:03 UTC

Peļņas

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

2026. g. 13. janv. 18:50 UTC

Peļņas

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

2026. g. 13. janv. 17:54 UTC

Tirgus saruna

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

2026. g. 13. janv. 17:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2026. g. 13. janv. 17:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

2026. g. 13. janv. 17:49 UTC

Tirgus saruna

Analysts Call For Potential Record Ethanol Output -- Market Talk

2026. g. 13. janv. 17:38 UTC

Tirgus saruna

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

2026. g. 13. janv. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 13. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. janv. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 13. janv. 17:19 UTC

Tirgus saruna

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

2026. g. 13. janv. 17:15 UTC

Tirgus saruna

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

25.23% augšup

Prognoze 12 mēnešiem

Vidējais 12.11 USD  25.23%

Augstākais 16 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

183 / 361 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat